Weight loss and dysgeusia in relapsed/refractory multiple myeloma patients treated with talquetamab

被引：1

作者：

Naqvi, Syed ^{[1
]}

Shrestha, Asis ^{[1
]}

Alzubi, Marah ^{[2
]}

Alrawabdeh, Jawad ^{[2
]}

Thanendrarajan, Sharmilan ^{[1
]}

Zangari, Maurizio ^{[1
]}

van Rhee, Frits ^{[1
]}

Schinke, Carolina ^{[1
]}

Al Hadidi, Samer ^{[1
]}

机构：

[1] Univ Arkansas Med Sci, Myeloma Ctr, Little Rock, AR USA

[2] Univ Jordan, Dept Internal Med, Amman, Jordan

来源：

EJHAEM | 2024年 / 5卷 / 04期

关键词：

dysgeusia; multiple myeloma; talquetamab; weight loss;

D O I：

10.1002/jha2.971

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Talquetamab is an approved therapy for relapsed/referactory multiple myeloma. This study examined dysgeusia and weight loss occurrences, alongside investigating symptom reversibility post-treatment cessation. Dysgeusia was prevalent, persisting in 15% of patients. On average, patients lost 6% of their weight during talquetemab treatment, with weight loss persisting in about half of the patients post-discontinuation. Weight loss and dysgeusia are important adverse events to consider while on talquetamab treatment. Extending dose intervals can potentially prevent such adverse events and should be studied in future prospective clinical trials complications and discomfort.

引用

页码：789 / 792

页数：4

共 50 条

[11] Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib
S Atrash
A Tullos
S Panozzo
M Bhutani
F Van Rhee
B Barlogie
S Z Usmani
Blood Cancer Journal, 2015, 5 : e272 - e272
[12] Talquetamab plus Daratumumab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Updated TRIMM-2 Results
Dholaria, Bhagirathbhai
Weisel, Katja
Mateos, Maria-Victoria
Goldschmidt, Harmut
Martin, Thomas
Morillo, Daniel
Reece, Donna
Rodriguez-Otero, Paula
Bhutani, Manisha
D'Souza, Anita
Oriol, Albert
Rosinol, Laura
Bahlis, Nizar
Bakshi, Kalpana
Kang, Lijuan
Vandenberk, Lien
Smit, M. Damiette
Wasch, Ralph
van de Donk, Niels
Chari, Ajai
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S476 - S477
[13] Phase 1b Results for Subcutaneous Talquetamab Plus Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma
Chari, Ajai
Hari, Parameswaran
Bahlis, Nizar J.
Mateos, Maria-Victoria
van de Donk, Niels W. C. J.
Dholaria, Bhagirathbhai
Garfall, Alfred L.
Goldschmidt, Hartmut
Kortuem, K. Martin
Krishnan, Amrita Y.
Martin, Thomas
Morillo Gilles, Daniel
Oriol, Albert
Reece, Donna E.
Rodriguez, Cesar
Rodriguez-Otero, Paula
San-Miguel, Jesus F.
Usmani, Saad Z.
Verona, Raluca I.
Lin, Shun Xin Wang
Prior, Thomas J.
Wade, Mark
Weiss, Brendan M.
Goldberg, Jenna D.
Askari, Elham
BLOOD, 2021, 138
[14] Real-World Safety and Efficacy of Talquetamab for Patients with Heavily Pretreated Relapsed-Refractory Multiple Myeloma
Shaikh, Hira
Lochner, Jonathan
Friend, Reed
Snyder, Jordan
Davis, James
Patrus, Gina
Dileo, Rachel
Ahmed, Nausheen
Mewawalla, Prerna
Poonsombudlert, Kittika
Struble, Emily
Wolcott, Allyson
Green, Kimberly
Sparrow, Samantha
Mushtaq, Muhammad Umair
Paul, Barry
Abdallah, Al-Ola
Strouse, Christopher
Hashmi, Hamza
Atrash, Shebli
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S87 - S88
[15] Real-World Safety and Early Efficacy of Talquetamab in Patients with Heavily-Pretreated Relapsed/Refractory Multiple Myeloma
Costa, Bruno
Tan, Carlyn
Shekarkhand, Tala
Firestone, Ross
Jurgens, Eric
Miller, Kevin
Lesokhin, Alexander
Shah, Gunjan
Korde, Neha
Rajeeve, Sridevi
Chung, David
Landau, Heather
Scordo, Michael
Hassoun, Hani
Maclachlan, Kylee
Shah, Urvi
Hultcrantz, Malin
Hamadeh, Issam
Giralt, Sergio
Mailankody, Sham
Usmani, Saad
Hashmi, Hamza
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S46 - S47
[16] Analysis of infections and parameters of humoral immunity in patients (pts) with relapsed/refractory multiple myeloma (RRMM) treated with talquetamab (tal) monotherapy in MonumenTAL-1.
Rodriguez-Otero, Paula
Schinke, Carolina D.
Chari, Ajai
Lipe, Brea
Lavi, Noa
Rasche, Leo
Vishwamitra, Deeksha
Skerget, Sheri
Verona, Raluca
Ma, Xuewen
Khedkar, Sheetal
Hilder, Brandi
Masterson, Tara J.
Campagna, Michela
Renaud, Thomas
Tolbert, Jaszianne A.
Heuck, Christoph
Smit, Marie-Anne Damiette
van de Donk, Niels W. C. J.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[17] Oral Symptom Assessment Using Patient Reported Outcomes (PRO) for Relapsed Multiple Myeloma Patients Treated with Talquetamab
Popat, Rakesh
Greenwood, Alexandra
Wilson, William
Mactier, Catriona
Cerner, Aviva
Worthington, Sarah
Russell, Jennifer
Jenkins, Chloe
Hughes, Daniel
Boyle, Eileen
McMillan, Annabel
Yong, Kwee
Lee, Lydia
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S123 - S123
[18] Peripheral Neuropathy Experience in Patients With Relapsed and/or Refractory Multiple Myeloma Treated With Carfilzomib
Martin, Thomas G.
ONCOLOGY-NEW YORK, 2013, 27 : 4 - 10
[19] Infectious Complications in Patients Treated with Idecabtagene Vicleucel for Relapsed and Refractory Multiple Myeloma
Little, Jessica S.
Shah, Parth
Sperling, Adam S.
Branagan, Andrew R.
Nadeem, Omar
Yee, Andrew J.
Raje, Noopur S.
Munshi, Nikhil C.
Hammond, Sarah
BLOOD, 2021, 138 : 3839 - +
[20] Prompt and Profound Responses with Talquetamab in Patients with Heavily Pretreated Relapsed-Refractory Multiple Myeloma - Another Bridging Therapy
Shaikh, Hira
Lochner, Jonathan
Davis, James
Snyder, Jordan
Friend, Reed
Patrus, Gina
DiLeo, Rachel
Mushtaq, Muhammad Umair
Green, Kimberly
Mewawalla, Prerna
Struble, Emily
Kussatz, Shannon
Ahmed, Nausheen
Abdallah, Al-Ola
Atrash, Shebli
Hashmi, Hamza
Paul, Barry
Strouse, Christopher
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S86 - S87

← 1 2 3 4 5 →